Zydus Cadila receives final approval from USFDA for Propafenone Hydrochloride Extended-Release Capsules

Zydus Cadila has received final approval from the USFDA to market Propafenone Hydrochloride ExtendedRelease Capsules USP, 225 mg, 325 mg, and 425 mg (US RLD: Rythmol Capsules). Propafenone is known as an anti-arrhythmic drug. It works by blocking the activity of certain electrical signals in the heart that can cause an irregular heartbeat.

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 315 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.552.25 as compared to the previous close of Rs. 556.05. The total number of shares traded during the day was 874801 in over 14645 trades.

The stock hit an intraday high of Rs. 573.35 and intraday low of 541.6. The net turnover during the day was Rs. 490823906.

Source : Equity Bulls

Keywords